StimLabs Launches Allacor P, First FDA-Cleared Umbilical Cord Particulate
Published: 11 Mar 2026
Author: Precedence Research
In January 2026, StimLabs launched Allacor P, a human umbilical cord device for acute and chronic wound management, which received FDA clearance in February 2024. It is the first graft derived from the human umbilical cord extracellular matrix (ECM) and is designed for various wound types. Allacor P's particulate format adapts to irregular wound surfaces and retains important ECM components like collagen I and hyaluronic acid.
StimLabs Boosts Wound Care Portfolio with New Device
The device received an A Code last year to facilitate its introduction in additional care sites. StimLabs has introduced Allacor P, a particulate, dehydrated human umbilical cord device designed to treat complex wounds by conforming to irregular surfaces and retaining vital ECM components like collagen I and hyaluronic acid. Following FDA clearance and an A Code designation, the product is expanding into new care settings, supported by positive clinician feedback and clinical evidence, including successful use in challenging, non-healing wounds.
According to Precedence Research, the chronic wound care medications market size accounted for USD 6.80 billion in 2025 and is predicted to increase from USD 7.28 billion in 2026 to approximately USD 13.38 billion by 2035, expanding at a CAGR of 7.00% from 2026 to 2035 as demand grows for advanced dressings, effective, and faster-acting, patient-focused therapeutic solutions.
The company is heavily invested in regenerative medicine, focusing on advanced solutions for wound care and surgical applications, including their Relese and Corplex P products. With a focus on strengthening its portfolio, StimLabs has conducted multi-center trials and is building on a strong, FDA-cleared, evidence-based portfolio to improve patient outcomes in both acute and chronic care.
New Era in Chronic Wound Healing
This launch is the first FDA-cleared human umbilical cord-derived particulate device designed to manage acute and chronic wounds. This innovation strengthened its position in the advanced wound care market by launching Allacor P, tissue-based human umbilical cord particulate device designed for complex wounds in private office settings. Complemented by the new sheet-form Theracor, this innovative, versatile portfolio advances regenerative medicine to improve patient outcomes.
A recent report by Precedence Research highlights that the chronic wound care medications market is benefiting from the growing adoption of advanced wound dressings and topicals, with a strong focus on enhancing healing rates for hard-to-heal wounds.